VRTX is trading 4.2% down at $500.27 as investors digest its planned $10 billion cash acquisition of Crinetics Pharmaceuticals.
- The deal, partly funded with new debt, expands Vertex into endocrine diseases with a portfolio of approved and late-stage assets.
- Shares are under pressure as the market evaluates near-term risks regarding integration, financing costs, and the projected timeline for the acquisition to become accretive to earnings.